Opportunities and challenges of co‑targeting epidermal growth factor receptor and autophagy signaling in non‑small cell lung cancer (Review)
- Authors:
- Xiaoju Wang
- Wenxin Li
- Ni Zhang
- Xiaoli Zheng
- Zhao Jing
-
Affiliations: Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang 310002, P.R. China, Cancer Research Institute, Hangzhou Cancer Hospital, Hangzhou, Zhejiang 310002, P.R. China - Published online on: May 20, 2019 https://doi.org/10.3892/ol.2019.10372
- Pages: 499-506
This article is mentioned in:
Abstract
 |
 |
 |
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mao Y, Yang D, He J and Krasna MJ: Epidemiology of lung cancer. Surg Oncol Clin N Am. 25:439–445. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Farsi A and Ellis PM: Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: First, second, and third-line. Front Oncol. 4:1572014. View Article : Google Scholar : PubMed/NCBI | |
|
Inal C, Yilmaz E, Piperdi B, Perez-Soler R and Cheng H: Emerging treatment for advanced lung cancer with egfr mutation. Expert Opin Emerg Drugs. 20:597–612. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Carrera S, Buque A, Azkona E, Aresti U, Calvo B, Sancho A, Arruti M, Nuño M, Rubio I, de Lobera AR, et al: Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: Biological basis and therapeutic strategies. Clin Transl Oncol. 16:339–350. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D, Yang Y and Zhao S: Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells. J Formos Med Assoc. 113:141–142. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sakuma Y, Matsukuma S, Nakamura Y, Yoshihara M, Koizume S, Sekiguchi H, Saito H, Nakayama H, Kameda Y, Yokose T, et al: Enhanced autophagy is required for survival in EGFR-independent EGFR-mutant lung adenocarcinoma cells. Lab Invest. 93:1137–1146. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lemmon MA, Schlessinger J and Ferguson KM: The egfr family: Not so prototypical receptor tyrosine kinases. Cold Spring Harb Perspect Biol. 6:a0207682014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Zhu J, Li Y, Lin T, Siclari VA, Chandra A, Candela EM, Koyama E, Enomoto-Iwamoto M and Qin L: Epidermal growth factor receptor (EGFR) signaling regulates epiphyseal cartilage development through β-catenin-dependent and -independent pathways. J Biol Chem. 288:32229–32240. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Brisken C and O'Malley B: Hormone action in the mammary gland. Cold Spring Harb Perspect Biol. 2:a0031782010. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HC, Su MY, Lo HC, Wu CC, Hu JR, Lo DM, Chao TY, Tsai HJ and Dai MS: Cancer metastasis and EGFR signaling is suppressed by amiodarone-induced versican V2. Oncotarget. 6:42976–42987. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Clapéron A, Mergey M, Nguyen Ho-Bouldoires TH, Vignjevic D, Wendum D, Chrétien Y, Merabtene F, Frazao A, Paradis V, Housset C, et al: EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J Hepatol. 61:325–332. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN and Ueno NT: Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 136:331–345. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, et al: First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): A phase 3, open-label, randomized study. Ann Oncol. 28:2443–2450. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, et al: Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): A randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 14:953–961. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Antonelli A, Fallahi P, Ulisse S, Ferrari SM, Minuto M, Saraceno G, Santini F, Mazzi V, D'Armiento M and Miccoli P: New targeted therapies for anaplastic thyroid cancer. Anticancer Agents Med Chem. 12:87–93. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Koustas E, Karamouzis MV, Mihailidou C, Schizas D and Papavassiliou AG: Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer. Cancer Lett. 396:94–102. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, et al: Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 14:7060–7067. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HA and Pao W: Targeted therapies: Afatinib-new therapy option for EGFR-mutant lung cancer. Nat Rev Clin Oncol. 10:551–552. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Cang S and Liu D: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 9:342016. View Article : Google Scholar : PubMed/NCBI | |
|
Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghi M, Rolfo C and Adamo V: Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. Crit Rev Oncol Hematol. 117:38–47. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 378:113–125. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G and Rosell R: Osimertinib in the treatment of non-small-cell lung cancer: Design, development and place in therapy. Lung Cancer (Auckl). 8:109–125. 2017.PubMed/NCBI | |
|
Piotrowska Z and Sequist LV: Epidermal growth factor receptor-mutant lung cancer: New drugs, new resistance mechanisms, and future treatment options. Cancer J. 21:371–377. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HA, Riely GJ and Lovly CM: Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res. 20:5898–5907. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rotow J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, et al: TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, et al: Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med. 9(pii): eaao43072017. View Article : Google Scholar : PubMed/NCBI | |
|
Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell. 132:27–42. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Levine B and Kroemer G: Autophagy in aging, disease and death: The true identity of a cell death impostor. Cell Death Differ. 16:1–2. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Z and Klionsky DJ: Eaten alive: A history of macroautophagy. Nat Cell Biol. 12:814–822. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cuervo AM and Wong E: Chaperone-mediated autophagy: Roles in disease and aging. Cell Res. 24:92–104. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
He C and Klionsky DJ: Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 43:67–93. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Guo M, Zhao S, Xu W, Shao J, Zhang F, Wu L, Lu Y and Zheng S: The update on transcriptional regulation of autophagy in normal and pathologic cells: A novel therapeutic target. Biomed Pharmacother. 74:17–29. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jing Z, Han W, Sui X, Xie J and Pan H: Interaction of autophagy with microRNAs and their potential therapeutic implications in human cancers. Cancer Lett. 356:332–338. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Chen H, Gao Y, Wang YW, Zhang GQ, Pan SH, Ji L, Kong R, Wang G, Jia YH, et al: Long noncoding RNA MALAT1 promotes aggressive pancreatic cancer proliferation and metastasis via the stimulation of autophagy. Mol Cancer Ther. 15:2232–2243. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Su Z, Yang Z, Xu Y, Chen Y and Yu Q: MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget. 6:8474–8490. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Z, Luo W, Wang J, Peng T, Sun G, Shi J, Li Z and Zhang B: Malat1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STMN1, RAB5A and ATG4D expression in glioma. Biochem Biophys Res Commun. 492:480–486. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang K, Liu CY, Zhou LY, Wang JX, Wang M, Zhao B, Zhao WK, Xu SJ, Fan LH, Zhang XJ, et al: APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat Commun. 6:67792015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen ZH, Wang WT, Huang W, Fang K, Sun YM, Liu SR, Luo XQ and Chen YQ: The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ. 24:212–224. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Henson E, Chen Y and Gibson S: EGFR family members' regulation of autophagy is at a crossroads of cell survival and death in cancer. Cancers (Basel). 9(pii): E272017. View Article : Google Scholar : PubMed/NCBI | |
|
Nyfeler B and Eng CH: Revisiting autophagy addiction of tumor cells. Autophagy. 12:1206–1207. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Alexandrova AY, Kopnin PB, Vasiliev JM and Kopnin BP: ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Exp Cell Res. 312:2066–2073. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou YY, Li Y, Jiang WQ and Zhou LF: MAPK/JNK signalling: A potential autophagy regulation pathway. Biosci Rep. 35(pii): e001992015.PubMed/NCBI | |
|
Yip PY: Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 4:165–176. 2015.PubMed/NCBI | |
|
Jung CH, Seo M, Otto NM and Kim DH: ULK1 inhibits the kinase activity of mTORC1 and cell proliferation. Autophagy. 7:1212–1221. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Kundu M, Viollet B and Guan KL: AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 13:132–141. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ernst M and Putoczki TL: Stat3: Linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol. 39:711–718. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Demaria M, Camporeale A and Poli V: Stat3 and metabolism: How many ways to use a single molecule? Int J Cancer. 135:1997–2003. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Niso-Santano M, Shen S, Adjemian S, Malik SA, Mariño G, Lachkar S, Senovilla L, Kepp O, Galluzzi L, Maiuri MC and Kroemer G: Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. Autophagy. 9:415–417. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Luo B, Lin Y, Jiang S, Huang L, Yao H, Zhuang Q, Zhao R, Liu H, He C and Lin Z: Endoplasmic reticulum stress eIF2α-ATF4 pathway-mediated cyclooxygenase-2 induction regulates cadmium-induced autophagy in kidney. Cell Death Dis. 7:e22512016. View Article : Google Scholar : PubMed/NCBI | |
|
Oh HM, Yu CR, Golestaneh N, Amadi-Obi A, Lee YS, Eseonu A, Mahdi RM and Egwuagu CE: STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J Biol Chem. 286:30888–30897. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oh HM, Yu CR, Dambuza I, Marrero B and Egwuagu CE: STAT3 protein interacts with Class O Forkhead transcription factors in the cytoplasm and regulates nuclear/cytoplasmic localization of FoxO1 and FoxO3a proteins in CD4(+) T cells. J Biol Chem. 287:30436–30443. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ray S, Zhao Y, Jamaluddin M, Edeh CB, Lee C and Brasier AR: Inducible STAT3 NH2 terminal mono-ubiquitination promotes BRD4 complex formation to regulate apoptosis. Cell Signal. 26:1445–1455. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kiprianova I, Remy J, Milosch N, Mohrenz IV, Seifert V, Aigner A and Kögel D: Sorafenib sensitizes glioma cells to the BH3 mimetic ABT-737 by targeting MCL1 in a STAT3-dependent manner. Neoplasia. 17:564–573. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun L, Hu L, Cogdell D, Lu L, Gao C, Tian W, Zhang Z, Kang Y, Fleming JB and Zhang W: MIR506 induces autophagy-related cell death in pancreatic cancer cells by targeting the STAT3 pathway. Autophagy. 13:703–714. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ and Chen KF: Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis. 4:e4852013. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada E, Bastie CC, Koga H, Wang Y, Cuervo AM and Pessin JE: Mouse skeletal muscle fiber-type-specific macroautophagy and muscle wasting are regulated by a Fyn/STAT3/Vps34 signaling pathway. Cell Rep. 1:557–569. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nechemia-Arbely Y, Khamaisi M, Rosenberger C, Koesters R, Shina A, Geva C, Shriki A, Klaus S, Rosen S, Rose-John S, et al: In vivo evidence suggesting reciprocal renal hypoxia-inducible factor-1 upregulation and signal transducer and activator of transcription 3 activation in response to hypoxic and non-hypoxic stimuli. Clin Exp Pharmacol Physiol. 40:262–272. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Tan J, Miao Y, Lei P and Zhang Q: The dual role of autophagy under hypoxia-involvement of interaction between autophagy and apoptosis. Apoptosis. 20:769–777. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Abdul Rahim SA, Dirkse A, Oudin A, Schuster A, Bohler J, Barthelemy V, Muller A, Vallar L, Janji B, Golebiewska A and Niclou SP: Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A. Br J Cancer. 117:813–825. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh DJ, Kuo WW, Lai YP, Shibu MA, Shen CY, Pai P, Yeh YL, Lin JY, Viswanadha VP and Huang CY: 17β-estradiol and/or estrogen receptor β attenuate the autophagic and apoptotic effects induced by prolonged hypoxia through HIF-1α-mediated BNIP3 and IGFBP-3 signaling blockage. Cell Physiol Biochem. 36:274–284. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wilkinson S and Ryan KM: Growth factor signaling permits hypoxia-induced autophagy by a HIF1alpha-dependent, BNIP3/3L-independent transcriptional program in human cancer cells. Autophagy. 5:1068–1069. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Karpathiou G, Sivridis E, Koukourakis M, Mikroulis D, Bouros D, Froudarakis M, Bougioukas G, Maltezos E and Giatromanolaki A: Autophagy and Bcl-2/BNIP3 death regulatory pathway in non-small cell lung carcinomas. APMIS. 121:592–604. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lai YC, Chuang YC, Chang CP and Yeh TM: Macrophage migration inhibitory factor has a permissive role in concanavalin A-induced cell death of human hepatoma cells through autophagy. Cell Death Dis. 6:e20082015. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Xia Y, Chen K, Li J, Liu T, Wang F, Lu J, Zhou Y and Guo C: Epigallocatechin-3-gallate attenuates apoptosis and autophagy in concanavalin A-induced hepatitis by inhibiting BNIP3. Drug Des Devel Ther. 10:631–647. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Z, Zhou L, Chen Z, Nice EC and Huang C: Stress management by autophagy: Implications for chemoresistance. Int J Cancer. 139:23–32. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, Ge W, Feng L, Lin X, Wang X, et al: EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 6:e186912011. View Article : Google Scholar : PubMed/NCBI | |
|
Li YY, Lam SK, Mak JC, Zheng CY and Ho JC: Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer. 81:354–361. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Du T, Dong X, Li Z, Wu G and Zhang R: Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress. Int J Oncol. 48:2558–2566. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R and Piperdi B: The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J Thorac Oncol. 8:693–702. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, et al: A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 7:1602–1608. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sotelo J, Briceño E and López-González MA: Adding chloroquine to conventional treatment for glioblastoma multiforme: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 144:337–343. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Boone BA, Bahary N, Zureikat AH, Moser AJ, Normolle DP, Wu WC, Singhi AD, Bao P, Bartlett DL, Liotta LA, et al: Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 22:4402–4410. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, et al: Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 10:1369–1379. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, et al: A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 10:1359–1368. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzoni A, Tiseo M, Capelletti M, Goldoni M, Tagliaferri S, Mutti A, et al: Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol. 78:460–468. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
So KS, Kim CH, Rho JK, Kim SY, Choi YJ, Song JS, Kim WS, Choi CM, Chun YJ and Lee JC: Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M. PLoS One. 9:e1140002014. View Article : Google Scholar : PubMed/NCBI | |
|
Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K and Yano S: The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer. 133:505–513. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rao S, Yang H, Penninger JM and Kroemer G: Autophagy in non-small cell lung carcinogenesis: A positive regulator of antitumor immunosurveillance. Autophagy. 10:529–531. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Katheder NS, Khezri R, O'Farrell F, Schultz SW, Jain A, Rahman MM, Schink KO, Theodossiou TA, Johansen T, Juhász G, et al: Microenvironmental autophagy promotes tumour growth. Nature. 541:417–420. 2017. View Article : Google Scholar : PubMed/NCBI |
